<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03577197</url>
  </required_header>
  <id_info>
    <org_study_id>MUMC-MO-2015-01</org_study_id>
    <nct_id>NCT03577197</nct_id>
  </id_info>
  <brief_title>Southeast Netherlands Advanced Metastatic Breast Cancer Registry</brief_title>
  <acronym>SONABRE</acronym>
  <official_title>Southeast Netherlands Advanced Breast Cancer Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ZonMw: The Netherlands Organisation for Health Research and Development</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Ziekenhuis Maastricht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Southeast Netherlands Advanced Breast Cancer (SONABRE) Registry is a real life&#xD;
      multi-center study. The registry aims to include all patients diagnosed with advanced breast&#xD;
      cancer as of 2007 in 12 hospitals in the Netherlands. Data on patient, tumor and treatment&#xD;
      characteristics are collected retrospectively from electronic medical files by trained&#xD;
      registry clerks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This SONABRE registry is an ongoing observational cohort study aiming at the inclusion of all&#xD;
      patients aged â‰¥18 years and diagnosed with advanced breast cancer in 2007-2020 in 12&#xD;
      hospitals in the Southeast of the Netherlands. Patients with de novo or recurrent advanced&#xD;
      breast cancer were identified from the hospital-based management information systems.&#xD;
      Specially trained registration clerks retrospectively collected data from the medical files&#xD;
      of the patients based on extensive medical chart review. Information was collected about&#xD;
      patient and tumour characteristics, type of treatment (surgery, radiotherapy and systemic&#xD;
      treatment, both neo-adjuvant, adjuvant and palliative), palliative treatment changes due to&#xD;
      adverse events, hospitalization, comorbidities and outcomes (progression and death). The&#xD;
      SONABRE Registry has already been effectively used to perform real-life studies on the use,&#xD;
      safety and (cost-)effectiveness of various systemic treatments used in patients diagnosed&#xD;
      with advanced breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2007</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>Treatment pattern</measure>
    <time_frame>up to 13 years</time_frame>
    <description>Treatment pattern per palliative treatment line; proportion of patients receiving chemotherapy, chemotherapy plus targeted therapy, endocrine therapy, endocrine therapy plus targeted therapy or targeted therapy alone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>up to 13 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>up to 13 years</time_frame>
    <description>Progression-free survival per systemic agent or palliative treatment line</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICER</measure>
    <time_frame>up to 13 years</time_frame>
    <description>Incremental cost-effectiveness ratio per QALY (quality-adjusted life year) gained of a new systemic drug compared with standard care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>QoL</measure>
    <time_frame>upt to 13 years</time_frame>
    <description>Quality of life; health state utility score calculated from the EQ-5D questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs</measure>
    <time_frame>up to 13 years</time_frame>
    <description>Costs of advanced breast cancer care from a hospital perspective</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Advanced Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patient diagnosed with advanced breast cancer between 2007-2020 in 12&#xD;
        hospitals in the Netherlands. No patients are being excluded. Also patients with no&#xD;
        systemic / active anti-tumour therapy for advanced breast cancer will be included. The&#xD;
        SONABRE Registry includes 12 hospitals: 1 academic, 8 teaching and 3 general hospitals. The&#xD;
        Netherlands counts 114 hospitals, including 8 academic, 25 teaching, 58 general and 23&#xD;
        categorical hospitals.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with de novo or recurrent advanced breast cancer in 2007-2020&#xD;
&#xD;
          -  Diagnosed with or treated for advanced breast cancer in one of the participating&#xD;
             hospitals&#xD;
&#xD;
          -  Participating hospitals (period of inclusion): Maastricht UMC+ (2007-2020), Zuyderland&#xD;
             hospitals Sittard/Heerlen (2007-2020), Amphia Hospital Breda (2007-2020), Catharina&#xD;
             Hospital Eindhoven (2007-2020), Elkerliek Hospital Helmond (2007-2020), Maxima Medical&#xD;
             Center Veldhoven/Eindhoven (2010-2020), Jeroen Bosch Hospital Den Bosch (2007-2020),&#xD;
             Laurentius Hospital Roermond (2007-2020), St. Annaziekenhuis Geldrop (2007-2020), St.&#xD;
             Elisabeth Hospital Tilburg (2007-2009), St. Jans Gasthuis Weert (2007-2020), VieCuri&#xD;
             Medical Center Venlo/Venray (2007-2020), all in the Netherlands.&#xD;
&#xD;
          -  Hospitals (and periods) were eligible for inclusion if (distant) registration from&#xD;
             Maastricht UMC+ was possible.&#xD;
&#xD;
          -  The inclusion period may be prolonged after 2020.&#xD;
&#xD;
        Exclusion Criteria: none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Vivianne CG Tjan-Heijnen, MD, PhD</last_name>
    <phone>+31 (0) 43 3877025</phone>
    <email>vcg.tjan.heijnen@mumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra ME Geurts, PhD</last_name>
    <phone>+31 (0) 43 3875217</phone>
    <email>sandra.geurts@mumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Multiple hospitals in the Netherlands (see Eligibility)</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivianne CG Tjan-Heijnen, MD, PhD</last_name>
      <phone>+31 (0) 43 3877025</phone>
      <email>vcg.tjan.heijnen@mumc.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <results_reference>
    <citation>Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC. Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer? Br J Cancer. 2015 Apr 28;112(9):1445-51. doi: 10.1038/bjc.2015.127. Epub 2015 Apr 16.</citation>
    <PMID>25880008</PMID>
  </results_reference>
  <results_reference>
    <citation>Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Borm GF, Tjan-Heijnen VC. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013 Oct;141(3):507-14. doi: 10.1007/s10549-013-2711-y. Epub 2013 Oct 9.</citation>
    <PMID>24104881</PMID>
  </results_reference>
  <results_reference>
    <citation>Lobbezoo D, Truin W, Voogd A, Roumen R, Vreugdenhil G, Dercksen MW, van den Berkmortel F, Smilde T, van de Wouw A, van Kampen R, van Riel J, Peters N, Peer P, Tjan-Heijnen VC. The role of histological subtype in hormone receptor positive metastatic breast cancer: similar survival but different therapeutic approaches. Oncotarget. 2016 May 17;7(20):29412-9. doi: 10.18632/oncotarget.8838.</citation>
    <PMID>27121067</PMID>
  </results_reference>
  <results_reference>
    <citation>Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FP, van Riel JM, Peters NA, de Boer M, Peer PG, Tjan-Heijnen VC. In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol. 2016 Feb;27(2):256-62. doi: 10.1093/annonc/mdv544. Epub 2015 Nov 16.</citation>
    <PMID>26578730</PMID>
  </results_reference>
  <results_reference>
    <citation>van Kampen RJW, Ramaekers BLT, Lobbezoo DJA, de Boer M, Dercksen MW, van den Berkmortel F, Smilde TJ, van de Wouw AJ, Peters FPJ, van Riel JMG, Peters NAJB, Tjan-Heijnen VCG, Joore MA. Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium. Eur J Cancer. 2017 Jul;79:238-246. doi: 10.1016/j.ejca.2017.01.027. Epub 2017 Feb 27.</citation>
    <PMID>28245951</PMID>
  </results_reference>
  <results_reference>
    <citation>Knapen LM, Geurts SME, Ibragimova KIE, Croes S, Vriens BEPJ, van den Berkmortel FWPJ, Dercksen MW, van de Wouw AJ, Pepels MJAE, de Fallois AOJ, Lobbezoo DJA, de Boer M, Tjan-Heijnen VCG. A real-life study on the implementation and effectiveness of exemestane plus everolimus per hospital type in patients with advanced breast cancer. A study of the Southeast Netherlands Advanced Breast Cancer registry. Breast. 2019 Apr;44:46-51. doi: 10.1016/j.breast.2019.01.001. Epub 2019 Jan 4.</citation>
    <PMID>30641299</PMID>
  </results_reference>
  <results_reference>
    <citation>Pouwels XGLV, Geurts SME, Ramaekers BLT, Erdkamp F, Vriens BEPJ, Aaldering KNA, van de Wouw AJ, Dercksen MW, Smilde TJ, Peters NAJB, Riel JMV, Pepels MJ, Heijnen-Mommers J, Joore MA, Tjan-Heijnen VCG, de Boer M. The relative effectiveness of eribulin for advanced breast cancer treatment: a study of the southeast Netherlands advanced breast cancer registry. Acta Oncol. 2020 Jan;59(1):82-89. doi: 10.1080/0284186X.2019.1670356. Epub 2019 Oct 4.</citation>
    <PMID>31583931</PMID>
  </results_reference>
  <results_reference>
    <citation>Schneider PP, Pouwels XGLV, Passos VL, Ramaekers BLT, Geurts SME, Ibragimova KIE, de Boer M, Erdkamp F, Vriens BEPJ, van de Wouw AJ, den Boer MO, Pepels MJ, Tjan-Heijnen VCG, Joore MA. Variability of cost trajectories over the last year of life in patients with advanced breast cancer in the Netherlands. PLoS One. 2020 Apr 9;15(4):e0230909. doi: 10.1371/journal.pone.0230909. eCollection 2020.</citation>
    <PMID>32271794</PMID>
  </results_reference>
  <results_reference>
    <citation>Pouwels XGLV, Ramaekers BLT, Geurts SME, Erdkamp F, Vriens BEPJ, Aaldering KNA, van de Wouw AJ, Dercksen MW, Smilde TJ, Peters NAJB, van Riel JMGH, Pepels MJ, Heijnen-Mommers J, Tjan-Heijnen VCG, de Boer M, Joore MA. An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry. Acta Oncol. 2020 Sep;59(9):1123-1130. doi: 10.1080/0284186X.2020.1775289. Epub 2020 Jun 16. Erratum in: Acta Oncol. 2021 May;60(5):645.</citation>
    <PMID>32544366</PMID>
  </results_reference>
  <results_reference>
    <citation>Claessens AKM, Ramaekers BLT, Lobbezoo DJA, van Kampen RJW, de Boer M, van de Wouw AJ, Dercksen MW, Geurts SME, Joore MA, Tjan-Heijnen VCG. Quality of life in a real-world cohort of advanced breast cancer patients: a study of the SONABRE Registry. Qual Life Res. 2020 Dec;29(12):3363-3374. doi: 10.1007/s11136-020-02604-4. Epub 2020 Aug 20.</citation>
    <PMID>32816222</PMID>
  </results_reference>
  <results_reference>
    <citation>Ibragimova KIE, Geurts SME, Croes S, Erdkamp F, Heijns JB, Tol J, Vriens BEPJ, Aaldering KNA, Dercksen MW, Pepels MJAE, Peters NAJB, van de Winkel L, Tilli DJP, Vriens IJH, de Boer M, Tjan-Heijnen VCG. Survival before and after the introduction of pertuzumab and T-DM1 in HER2-positive advanced breast cancer, a study of the SONABRE Registry. Breast Cancer Res Treat. 2021 Jul;188(2):571-581. doi: 10.1007/s10549-021-06178-8. Epub 2021 Mar 20.</citation>
    <PMID>33743103</PMID>
  </results_reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 11, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2018</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Ziekenhuis Maastricht</investigator_affiliation>
    <investigator_full_name>V.C.G. Tjan-Heijnen</investigator_full_name>
    <investigator_title>Professor of medical oncology</investigator_title>
  </responsible_party>
  <keyword>Breast neoplasms</keyword>
  <keyword>Neoplasm Metastasis</keyword>
  <keyword>Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

